Table 3. Multivariate analyses of the factors associated with risks for recurrence of MPE in EGFR/ALK mutated patients.

Variable	HR	95% CI	P
Targeted therapy after the first thoracentesis within 30 days	0.438	0.250–0.768	0.004
CRP (≥1.35 mg/L)	2.523	1.183–5.381	0.017
s-LDH (≥197.5 U/L)	2.305	1.295–4.103	0.005
p-Glucose (≥6.25 mmol/L)	2.148	1.242–3.715	0.006
p-CEA (≥869.4 μg/L)	2.150	1.225–3.774	0.008

MPE, malignant pleural effusion; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; HR, hazard ratio; CI, confidence interval; CRP, C-reaction protein; s-LDH, serum lactate dehydrogenase; p-Glucose, pleural glucose; p-CEA, pleural carcinoembryonic antigen.